Table 2. Compliance with aspirin... | American Society of Hematology

Table 2.

Compliance with aspirin treatment according to pill counting in 243 evaluable patients with ET

	Fully compliant (n =218)*	Partially compliant (n = 21)†	Noncompliant (n = 4)‡	Global P
Sex				.23
Male	104 (47.7)	6 (28.6)	2 (50)
Female	114 (52.3)	15 (71.4)	2 (50)
Age at enrollment, median (IQR), y	60 (51.3-67)	54 (45-66)	54 (43.3-64)	.21
TXB₂ at visit 2, median (IQR), ng/mL	18.6 (8.9-42.9)	22.8 (13.6-37)	46.5 (24-107.8)	.40
Treatment, 100 mg				.60
Once daily	73 (33.5)	10 (47.6)	2 (50)
Twice daily	71 (32.6)	7 (33.3)	1 (25)
Thrice daily	74 (33.9)	4 (19.1)	1 (25)

	Fully compliant (n =218)*	Partially compliant (n = 21)†	Noncompliant (n = 4)‡	Global P
Sex				.23
Male	104 (47.7)	6 (28.6)	2 (50)
Female	114 (52.3)	15 (71.4)	2 (50)
Age at enrollment, median (IQR), y	60 (51.3-67)	54 (45-66)	54 (43.3-64)	.21
TXB₂ at visit 2, median (IQR), ng/mL	18.6 (8.9-42.9)	22.8 (13.6-37)	46.5 (24-107.8)	.40
Treatment, 100 mg				.60
Once daily	73 (33.5)	10 (47.6)	2 (50)
Twice daily	71 (32.6)	7 (33.3)	1 (25)
Thrice daily	74 (33.9)	4 (19.1)	1 (25)

Data are n (%), unless otherwise indicated. The P values were calculated using the Kruskal-Wallis test or χ² test for continuous or discrete variables, respectively.

All 9 pills in the 3 days before visit 3.

†

Six to 8 pills in the 3 days before visit 3.

‡

No pill in the 3 days before visit 3.

View Large

This Feature Is Available To Subscribers Only